Navigation Links
Nile Therapeutics Announces Top-Line Results in Clinical Trial Evaluating the Subcutaneous Infusion of Cenderitide, Meets Primary Endpoint
Date:11/16/2011

eptable bioavailability profile;
  • Cenderitide's PK profile achieved steady-state when delivered through subcutaneous infusion;
  • Weight-based dosing reduced PK variability, as compared to a fixed dosing regimen.

  • "We believe the data from this trial proves that dosing cenderitide with subcutaneous pump technology is a viable strategy for dosing heart failure patients in the out-patient setting," said Hsiao Lieu, MD, Vice President of Clinical Research at Nile. "We now believe that we understand the target dose range for continuous subcutaneous delivery of cenderitide to heart failure patients.  In the next clinical trial, a Phase 2 trial, we hope to test our hypothesis that cenderitide can help reduce hospital re-admission in the post-acute period following ADHF."

    "When dosed continuously in the out-patient setting during the post-acute period, we believe cenderitide has the potential to reduce the re-hospitalization rate following ADHF," said Richard Brewer, Executive Chairman Nile. "If effective, cenderitide may be able to fundamentally change the treatment paradigm of ADHF, potentially reducing the overall financial burden of heart failure on the system."

    About Heart Failure
    Heart failure is the fastest-growing clinical cardiac disease in the U.S. according to the American Heart Association, affecting over 5 million Americans. Over 1 million patients in the U.S. each year are hospitalized with ADHF, an acute exacerbation of heart failure. ADHF is the is the most frequent cause of hospital admission in the U.S. for patients older than 65 years, generating annual inpatient costs of more than $35 billion. Within 90 days following admission for ADHF, approximately 40% of patients return to the hospital. Nile believes that a decrease in the ADHF re-hospitalization rate, which is the clinical target of the cenderitide development program, could both improve the quality of life for patients and decrease the ann
    '/>"/>

    SOURCE Nile Therapeutics, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4

    Related biology technology :

    1. Nile Therapeutics Reports 2011 Third Quarter Financial Results
    2. Cell Therapeutics, Inc. Reports Results of Annual Meeting of Shareholders
    3. Orexigen® Therapeutics Reports Third Quarter Financial Results
    4. Silence Therapeutics Provides Corporate and Development Update
    5. Halozyme Therapeutics Reports Third Quarter 2011 Financial Results
    6. Regado Biosciences, Inc. Presents Positive Efficacy and Safety Substudy Data from the Phase 2b RADAR Trial for the REG1 Anticoagulation System at the Transcatheter Cardiovascular Therapeutics (TCT) Symposium 2011
    7. Karyopharm Therapeutics Closes $10 Million Series A2 Financing to Expand Planned Phase 1 Program of Oral Selective Inhibitors of Nuclear Export (SINE) for Cancer
    8. Halozyme Therapeutics Announces Data From Two Phase 1 Studies of PEGPH20 Demonstrating Targeting of Hyaluronan in Tumor Stroma
    9. United Therapeutics Corporation Reports Third Quarter 2011 Financial Results
    10. Amsterdam Molecular Therapeutics Provides Operations Update & Strategic Review of Pipeline
    11. Cell Therapeutics, Inc. (CTI) Reports Third Quarter Financial Results and Milestones
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:7/12/2014)... (PRWEB) July 12, 2014 ... various reagents used in the life science ... the life science reagents market towards remarkable ... manufacturers and providers of life science reagents. ... Report: http://www.transparencymarketresearch.com/life-sciences-reagents-analytical-reagents.html . , The global ...
    (Date:7/11/2014)... EPFL and the University of  Geneva ... John P. Donoghue . The American neuroscientist is ... . The new Wyss Center for Bio- ... Geneva , has named as its director one ... Donoghue , founder of Brown University,s Institute for Brain ...
    (Date:7/10/2014)... July 10, 2014 Product and ... very low abundance and are often “lost in ... time-consuming. , Join presenters Dr. Rowel Tobias, Senior ... John Anders, Head of Quality at Nanotherapeutics, Inc., ... that can speed detection and quantitation while achieving ...
    (Date:7/10/2014)... 10, 2014 Robert Harman, DVM, Founder and ... is proud to announce the relaunch of his highly informative ... new series called “ What are Stem Cells ?” ... and straightforward foundation in the basics of stem cell therapy ... the right type of treatment when considering regenerative medicine. , ...
    Breaking Biology Technology:Transparency Market Research: Life Science Reagents Market- PCR Reagent Kits, Cell and Tissue Culture, Flow Cytometry, Electrophoresis and Chromatography 2Transparency Market Research: Life Science Reagents Market- PCR Reagent Kits, Cell and Tissue Culture, Flow Cytometry, Electrophoresis and Chromatography 3John P. Donoghue is Taking the Lead at the Wyss Center and is Appointed Professor at EPFL and University of Geneva 2John P. Donoghue is Taking the Lead at the Wyss Center and is Appointed Professor at EPFL and University of Geneva 3Novel Ms Techniques Speed Detection of Biopharmaceutical Product and Process Impurities, New Webinar Hosted by Xtalks 2Robert Harman, DVM Talks About What Stem Cells are in His Latest Blog Series for Vet-Stem, Inc. 2Robert Harman, DVM Talks About What Stem Cells are in His Latest Blog Series for Vet-Stem, Inc. 3
    ... , COLUMBUS, Ohio, Nov. 30 The ... the nation,s first minority business early-stage capital summits. The ... "Transforming the Landscape of Business in America: A Minority Business ... national minority business leaders and local minority entrepreneurs. , ...
    ... Minn., Nov. 30 Acuo Technologies, developers of high-performance ... today announced contracting with Allina Hospitals and Clinics for ... of image storage across the Allina network of hospitals, ... on the Acuo Technologies DICOM Services Grid(TM) Software. ...
    ... , ... 2 (GPP2), a key guidance document for the publication of ... British Medical Journal (BMJ). "The publication of GPP2 in BMJ ... guidance for industry sponsored research and the publication of study ...
    Cached Biology Technology:Ohio Capital Fund Announces Sponsorship of Minority Business Conference 2Acuo Technologies Announces Contract for Vendor Neutral Archive With Allina Hospitals and Clinics 2Acuo Technologies Announces Contract for Vendor Neutral Archive With Allina Hospitals and Clinics 3ISMPP Announces Publication of Good Publication Practice for Communicating Company-Sponsored Medical Research: GPP2 Guidelines Published in the BMJ 2ISMPP Announces Publication of Good Publication Practice for Communicating Company-Sponsored Medical Research: GPP2 Guidelines Published in the BMJ 3
    (Date:7/11/2014)... Society shows that no-take zones in Belize can ... lobster, conch, and fish recover from overfishing, but ... The reporttitled "Review of the Benefits of No-Take ... no-take areas around the world. The report was ... in marine protected areas and fisheries management. The ...
    (Date:7/11/2014)... Tenn., July 11, 2014--Researchers at the Department of ... R&D 100 awards, presented by R&D Magazine in ... , "These awards recognize the tremendous value of ... Moniz. "Research and development at the National Labs ... challenges and pursue the scientific and technological innovations ...
    (Date:7/11/2014)... New South Wales, Australia when NASA,s Aqua satellite passed ... July 11 (12:35 p.m. local time/11:35 p.m. EDT on ... Wales (NSW), the Moderate Resolution Imaging Spectroradiometer (MODIS) aboard ... spotted smoke (light brown) from various fires. Actively burning ... red. , The New South Wales, Australia Government website ...
    Breaking Biology News(10 mins):Belize's lobster, conch, and fish populations rebuild in no-take zones 2ORNL wins eight R&D 100s 2ORNL wins eight R&D 100s 3ORNL wins eight R&D 100s 4
    ... , Today, Andrew Viterbi, Donald Bitzer and John Daugman ... Inventors Hall of Fame at the United States Patent ... and their accomplishments are in part a testimony to ... Viterbi, an electrical engineer and cofounder of wireless ...
    ... appearing in the Journal of Nutritional Biochemistry demonstrates that ... chronic high blood pressure (hypertension) by increasing the activity ... heart tissue. Grapes are a known natural source ... be responsible for the beneficial effects observed with grape ...
    ... that aimed to understand how the cancer drug everolimus ... trastuzumab has left researchers contemplating a puzzle. , The ... rates for some patients with early breast cancer when ... results suggest this benefit is achieved independently of the ...
    Cached Biology News:New National Inventors Hall of Fame inductees received vital NSF support 2New National Inventors Hall of Fame inductees received vital NSF support 3New National Inventors Hall of Fame inductees received vital NSF support 4Study uncovers mechanism for how grapes reduce heart failure associated with hypertension 2Study confirms everolimus can overcome trastuzumab resistance in HER-2 positive early breast cancer 2Study confirms everolimus can overcome trastuzumab resistance in HER-2 positive early breast cancer 3
    ... Anti-PRK2 MW 140kDa ... Immunogen Peptide spanning amino acids ... Purification immunoaffinity purified Quality ... RIPA lysates from HeLa cells. ...
    ...
    Replacement Parts for Electrophoresis Apparatus...
    Sprague-Dawley rats, 7-8 weeks old, mixed gender; tissue is collected fresh, frozen on dry ice within minutes of sacrifice and stored at -20C; individual tissue weight approx. 0.05 gram....
    Biology Products: